Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Teva, Lonza In Venture To Copy Biotech Drugs

By Pharmaceutical Processing | January 20, 2009

NEW YORK (AP) — Generic drug developer Teva Pharmaceutical Industries Ltd. and Lonza Group Ltd. said Monday they are forming a joint venture to make and sell copies of biotechnology-based drugs.Financial details of the deal were not disclosed. The products are known as biosimilar, or sometimes called biogeneric, because they are attempts at copies of drugs that are made using living cells, unlike more traditional chemical-based drugs. Unlike generic versions of chemical-based drugs, there is currently no process in the U.S. for reviewing and approving copies of biosimilars. The biotechnology industry and generic drug industry have been fighting over patent issues, market exclusivity issues and how to make the copies safely. Because the compounds are made using living cells, many in the industry say any copy would actually be a new drug because the process would have to be recreated. Advocates and lobbyists for both sectors expect Congress to take up the issue again this year.”We had identified biosimilars as a major growth driver for Teva in our long-term strategy and have been augmenting our knowledge base, capabilities and infrastructure to position Teva as a leader in this market”, said Teva President and Chief Executive Shlomo Yanai, in a statement. The joint venture is expected to start during the first quarter of 2009. Teva is based in Israel and Lonza is based in Switzerland. Teva, and several other companies have been beefing up their biotech holdings in anticipation of the biosimilar market opening up. Last January, Teva bought biotechnology company CoGenesys for $400 million. More recently Merck & Co.’s announced a $1.5 billion, six-year program to develop copies of biotech drugs.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE